|
|
|
| Clinical Study on Glucocorticoid-Induced Osteoporosis Treated with Desumab Combined with Calcitonin Injection |
| LIN Ling, WU Shiyong |
| Department of Pharmacy,Jiangle County Hospital,Sanming Fujian 353300 |
|
|
|
|
Abstract 【Objective】To investigate the clinical efficacy of disumab combined with salmon calcitonin injection in the treatment of glucocorticoid-induced osteoporosis (GIOP). 【Methods】A total of 204 patients with GIOP admitted to our hospital from July 2021 to January 2023 were selected and divided into the control group (n=103) and the observation group (n=101) according to random number table method. The control group was treated with calcitonin injection on the basis of conventional treatment, while the observation group was treated with sulizumab injection on the basis of control group. Both groups were treated for 12 months. The clinical efficacy, total incidence of adverse drug reactions, bone mineral density [osteocalcin (N-MID), procollagen type Ⅰ N-terminal peptide (PⅠNP), β-collagen special sequence (β-CTX), alkaline phosphatase (BAP), calcitonin (CT)], and dysfunction [assessed by Oswestry Disability Index (ODI) score] and pain [visual analogue pain scale (VAS)] before and after treatment were compared between the two groups.【Results】After treatment, L2~4, bone mineral density and BAP levels of femoral neck in observation group were higher than those in control group, while β-CTX, N-MID, PⅠNP and CT were lower than those in control group, with statistical significance (P<0.05). After 6 months and 12 months of treatment, VAS and ODI scores in observation group were lower than those in control group (P<0.05). The total effective rate of observation group (91.09%) was higher than that of control group (80.58%) (P<0.05). There was no significant difference in the total incidence of adverse drug reactions between the two groups (P>0.05). 【Conclusion】Disumab combined with calcitonin injection is effective in the treatment of GIOP patients, which can increase bone mineral density, relieve pain and dysfunction, improve bone metabolism indexes, and is safe and reliable.
|
|
Received: 17 June 2024
|
|
|
|
|
|
[1] JHA S S. Glucocorticoid-Induced Osteoporosis (GIOP)[J].Indian J Orthop,2023, 57(Suppl 1):181-191.
[2] ANASTASILAKI E, PACCOU J, GKASTARIS K, et al. Glucocorticoid-induced osteoporosis: an overview with focus on its prevention and management[J].Hormones (Athens),2023, 22(4):611-622.
[3] LEBOFF M S, GREENSPAN S L, INSOGNA K L, et al. The clinician's guide to prevention and treatment of osteoporosis[J].Osteoporos Int,2022, 33(10):2049-2102.
[4] TAMECHIKA S Y, OHMURA S I, MAEDA S, et al. Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids[J].J Bone Miner Metab,2023, 41(2):203-211.
[5] 中国医师协会风湿免疫科医师分会,中华医学会风湿病学分会,中华医学会骨质疏松和骨矿盐疾病分会,等. 2020版中国糖皮质激素性骨质疏松症防治专家共识[J].中华内科杂志,2021,60(1):13-21.
[6] HE S, RENNE A, ARGANDYKOV D, et al. Comparison of an emoji-based visual analog scale with a numeric rating scale for pain assessment[J].JAMA,2022, 328(2):208-209.
[7] LAW K K P, LEE P L, KWAN W W, et al. Cross-cultural adaptation of Cantonese (Hong Kong) Oswestry Disability Index version 2.1b[J].Eur Spine J,2021, 30(9):2670-2679.
[8] 陈定中,杨益,李超艺,等. 唑来膦酸联合鲑降钙素对骨质疏松症骨折患者术后骨痛及骨折愈合的影响[J].中国临床药理学杂志,2022,38(16):1863-1867.
[9] OELZNER P, EIDNER T, PFEIL A. Glucocorticoid-induced osteoporosis-Focus treatment (part 2)[J].Z Rheumatol,2022, 81(2):125-133.
[10] 姜平,赵佳男,魏凯,等. 地舒单抗治疗类风湿关节炎患者骨质疏松症有效性和安全性的Meta分析[J].中国免疫学杂志,2023,39(9):1928-1933.
[11] 魏祺,郑苗,翁程伟,等. 地舒单抗治疗绝经后骨质疏松症的早期疼痛评分和功能障碍指数[J].中华骨科杂志,2022,42(12):768-775.
[12] 王猛,党星波,周永春,等. 地舒单抗治疗老年性骨质疏松症疗效及对患者骨密度、骨代谢的影响[J].陕西医学杂志,2023,52(10):1395-1398.
[13] 张琪,崔容海,何龙希,等. 密固达与地舒单抗治疗更年期女性骨质疏松症疗效及对患者血清骨代谢标志物影响[J].临床军医杂志,2023,51(6):652-654. |
|
|
|
2024, Vol. 41 
